头孢地尔药敏试验的系统评价:特洛伊木马的阿喀琉斯之踵?
该系统评价评估了头孢地尔药敏试验方法的性能。商业微量肉汤稀释法(BMD)面板中UMIC®分类一致率超90%,但基本一致率仅75%-85%且极重大误差约15%;纸片扩散法分类一致率79.4%、重大误差29.0%;梯度扩散法极重大误差高达41.1%,应限制使用。EUCAST与CLSI/FDA折点差异及拖尾现象进一步影响判读。
要点
- 商业BMD面板中UMIC®分类一致率超90%,但基本一致率仅75%-85%,极重大误差约15%。
- 纸片扩散法分类一致率79.4%,重大误差29.0%,其中MASTDISCS®表现最佳。
- 梯度扩散法极重大误差高达41.1%,应限制使用。
核心结论
- 头孢地尔药敏试验方法标准化和严格验证对确保MDR感染患者可靠药敏结果至关重要。
研究设计与样本
- 该系统评价评估了头孢地尔药敏试验方法,包括商业BMD面板、纸片扩散法和梯度扩散法。
主要发现
- 商业BMD面板中UMIC®分类一致率超90%,但基本一致率75%-85%,极重大误差约15%。
- 纸片扩散法总体分类一致率79.4%,重大误差29.0%,极重大误差13.9%;MASTDISCS®汇总分类一致率93.2%,重大误差5.4%,极重大误差6.3%。
- 梯度扩散法极重大误差率高达41.1%,表现最差。
- EUCAST与CLSI/FDA折点差异导致各实验室药敏分类不一致。
- 拖尾终点和抑菌圈内微菌落进一步干扰判读,尤其纸片扩散法。
关键数值与推荐
- 商业BMD面板基本一致率75%-85%,低于90%期望阈值,极重大误差约15%。
- 纸片扩散法重大误差中位数29%,MASTDISCS®汇总分类一致率93.2%。
- 梯度扩散法极重大误差率41.1%。
临床怎么用
- 优先选择性能较优的商业BMD面板(如UMIC®)进行头孢地尔药敏试验。
- 纸片扩散法需注意高重大误差风险,判读时警惕拖尾和微菌落。
- 限制梯度扩散法用于头孢地尔药敏试验。
- 关注EUCAST与CLSI/FDA折点差异对结果分类的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cefiderocol, an innovative siderophore cephalosporin, presents a novel therapeutic option against a spectrum of multidrug-resistant (MDR) Gram-negative pathogens. Nevertheless, resistance remains a formidable challenge, particularly among metallo-beta-lactamase (MBL)-producing organisms. Accurate antimicrobial susceptibility testing (AST) for cefiderocol is complex due to the labour-intensive broth microdilution (BMD) reference method requiring iron-depleted media, lacking reproducibility. In response, commercial AST methods, including BMD panels, disc diffusion (DD), and gradient diffusion test, have been developed. Commercial BMD panels, such as ComASP® and UMIC®, demonstrate potential, with the latter reaching categorical agreement (CA) above 90%. Yet, essential agreement (EA) remains between 75% and 85%, below the 90% desired threshold, with very major errors (VMEs) occurring frequently (∼15%). Disc diffusion (DD) methods, while practical, often overcall resistance, leading to major errors (MEs) with a median across studies of 29%. Among disc manufacturers, MASTDISCS® performed best, with a pooled CA of 93.2%, 5.4% ME and 6.3% VME. Overall, discs recorded a CA of 79.4%, MEs of 29.0% and VMEs of 13.9%. Gradient diffusion tests performed least favourably among all methods, exhibiting a notably high VME rate of 41.1%, and their use should be limited. Cefiderocol AST is further complicated by disparities between European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI)/Food and Drug Administration (FDA) breakpoints, contributing to inconsistencies in susceptibility categorization across laboratories. Additional challenges, such as trailing endpoints and microcolonies within inhibition zones, further confound readings, especially in DD assays. Consequently, the standardization and rigorous validation of the best performing cefiderocol AST methodologies are imperative to ensure reliable susceptibility outcomes and optimized outcomes for patients with MDR infections.
引用
- Tsakri D, Ferous S, Baltas I, et al. The Achilles' heel of the Trojan Horse? A systematic evaluation of cefiderocol susceptibility testing. J Antimicrob Chemother. 2025. PMID: 41117673. doi:10.1093/jac/dkaf391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。